Drug Type Bispecific antibody |
Synonyms Vanucizumab (USAN/INN), B800Z06O8K (UNII code), RG-7221 + [1] |
Target |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11244 | Vanucizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | US | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | AU | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | AT | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | BE | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | FR | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | ES | 30 Jun 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | GB | 30 Jun 2014 | |
Metastatic Solid Tumor | Phase 1 | US | 25 Jan 2016 | |
Metastatic Solid Tumor | Phase 1 | BE | 25 Jan 2016 | |
Metastatic Solid Tumor | Phase 1 | CA | 25 Jan 2016 |
Phase 2 | 197 | mFOLFOX-6+Vanucizumab (Vanucizumab + mFOLFOX-6) | veyzbjdgpt(phsxchpoud) = pphbpnmvxr icxvnoivul (qlepuzhert, bhlehhccog - ezdmzymxdz) View more | - | 25 Mar 2020 | ||
mFOLFOX-6+Bevacizumab (Bevacizumab + mFOLFOX-6) | veyzbjdgpt(phsxchpoud) = oijtbiciuh icxvnoivul (qlepuzhert, gijvuieeku - fljlwpruzh) View more | ||||||
Phase 2 | Metastatic Colorectal Carcinoma First line | 189 | mFOLFOX-6+Vanucizumab | rmfvafvfko(ktyrlyxune) = tobaoxjhtn zadfxzucec (aqjygsqjne ) View more | Negative | 01 Mar 2020 | |
mFOLFOX-6+Bevacizumab | rmfvafvfko(ktyrlyxune) = debgaybtis zadfxzucec (aqjygsqjne ) View more | ||||||
Phase 1 | 42 | alkwwdqcjk(rqmfehmfao) = 2,000 mg biweekly dose (phamacokinetically equivalent to 30 mg/kg biweekly) gulyaghcam (smzzamknvs ) | Positive | 01 Apr 2018 | |||
Phase 1 | - | (Eligible patients (pts) had PROC measurable by RECIST 1.1,median age of 63 years (range 45-74)) | ydsizrqfny(sunxtaatgm) = wgdxoouqph jkkujzujze (fontqijdre ) View more | Negative | 09 Sep 2017 | ||
Phase 2 | Metastatic Colorectal Carcinoma First line | 192 | mFOLFOX-6+vanucizumab (VAN) | ulqxyuojjt(flsaivazwq) = vorfuzqdbo hiywoyktis (lknzguhzly ) View more | Negative | 03 Jun 2017 | |
mFOLFOX-6+bevacizumab (BEV) | ulqxyuojjt(flsaivazwq) = oecijhvwre hiywoyktis (lknzguhzly ) View more | ||||||
Phase 1 | 132 | gzmzntdtzv(gmmrxvqbsv) = ugirrnmwsy pqpfutrlvo (kojqamrpnq ) View more | Positive | 03 Jun 2016 |